Hope in sight TM

Our research is bringing hope to people affected by vision loss and blindness

Donate Now

Hear from our experts

Hear our scientists discuss the latest developments in vision research - from work in the laboratory to develop new gene therapies,  to clinical trials testing cutting-edge new treatments for eye disease.  

Eye health resource

About one in five Australian children has an undetected eye problem. Our new guide is full of information on conditions that can affect young eyes, the warning signs to look out for and ways you can protect children’s vision for the future.

Science and Research

The Keratoconus International Consortium (KIC) is a worldwide collaboration led by the Centre for Eye Research Australia.


In this video, learn about CERA’s research into gene therapies that could halt or even reverse vision loss in patients with conditions such as inherited retinal diseases and glaucoma.

Donate to CERA

With your support, there’s hope in sight.

Your gift will contribute to our world-leading vision research, making a real difference to people affected by vision loss and blindness.

Donate now

Take part in research

We conduct world-leading clinical trials for a range of eye conditions.

Learn more about taking part in clinical trials for conditions like age-related macular degeneration, glaucoma, diabetic retinopathy and more.

Learn more

Latest News


24 October 2021

The team developing Australia’s bionic eye have achieved a major milestone in their research.


16 September 2021

CERA researchers have received a major funding boost for projects using artificial intelligence and powerful imaging technologies to prevent vision loss and gain greater insight into the ageing process.


24 August 2021

New research tracking the progress of Bietti Crystalline Dystrophy provides a useful template for investigating other inherited retinal diseases.


28 September 2021

Two new key appointments will boost CERA’s research credentials in gene therapy and ocular oncology.

Eye-news emails are sent to subscribers once a month

Newsletter Subscribe
Receive Appeals